Literature DB >> 21105689

Transcript profiling and RNA interference as tools to identify small molecule mechanisms and therapeutic potential.

Rahul Palchaudhuri1, Paul J Hergenrother.   

Abstract

The identification of the mechanism of action and therapeutic potential of bioactive small molecules remains a considerable challenge in the field of drug discovery and chemical biology. Apart from traditional target identification techniques, new tools have emerged that can significantly aid mechanism elucidation efforts. The development of pattern matching algorithms that compare transcription profile data to analogous data on compounds with known cellular targets allows for mechanistic insights without the need to synthesize chemically modified probes. In addition, such methods can be used to connect small molecules to particular disease states, thus aiding the rational identification of candidate therapeutics. Another method with considerable potential is whole-genome RNAi screening, a technique that can identify critical upstream proteins involved in a small molecule's mechanism of action. Several proof-of-concept studies using compounds with known cellular targets suggest this tool will enable mechanistic characterization of bioactive small molecules with unknown mechanisms. This Review highlights recent successes in using these pattern matching and chemical genetic tools, with the goal of uncovering small molecule mechanisms and identifying therapeutic candidates for disease treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21105689      PMCID: PMC3121534          DOI: 10.1021/cb100310h

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  49 in total

1.  Identifying the proteins to which small-molecule probes and drugs bind in cells.

Authors:  Shao-En Ong; Monica Schenone; Adam A Margolin; Xiaoyu Li; Kathy Do; Mary K Doud; D R Mani; Letian Kuai; Xiang Wang; John L Wood; Nicola J Tolliday; Angela N Koehler; Lisa A Marcaurelle; Todd R Golub; Robert J Gould; Stuart L Schreiber; Steven A Carr
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-02       Impact factor: 11.205

Review 2.  Identification of the cellular targets of bioactive small organic molecules using affinity reagents.

Authors:  Benjamin J Leslie; Paul J Hergenrother
Journal:  Chem Soc Rev       Date:  2008-05-23       Impact factor: 54.564

3.  Candidate therapeutic agents for hepatocellular cancer can be identified from phenotype-associated gene expression signatures.

Authors:  Chiara Braconi; Fanyin Meng; Erica Swenson; Lyudmyla Khrapenko; Nianyuan Huang; Tushar Patel
Journal:  Cancer       Date:  2009-08-15       Impact factor: 6.860

4.  Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway.

Authors:  Eduardo Vilar; Bhramar Mukherjee; Rork Kuick; Leon Raskin; David E Misek; Jeremy M G Taylor; Thomas J Giordano; Samir M Hanash; Eric R Fearon; Gad Rennert; Stephen B Gruber
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

5.  Anticancer properties of 2-piperidyl analogues of the natural indole phytoalexin 1-methoxyspirobrassinol.

Authors:  Roman Mezencev; Peter Kutschy; Aneta Salayová; Zuzana Curillová; Ján Mojzis; Martina Pilátová; John McDonald
Journal:  Chemotherapy       Date:  2008-09-04       Impact factor: 2.544

6.  Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses.

Authors:  Hiromichi Ebi; Shuta Tomida; Toshiyuki Takeuchi; Chinatsu Arima; Takahiko Sato; Tetsuya Mitsudomi; Yasushi Yatabe; Hirotaka Osada; Takashi Takahashi
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

7.  Highly parallel identification of essential genes in cancer cells.

Authors:  Biao Luo; Hiu Wing Cheung; Aravind Subramanian; Tanaz Sharifnia; Michael Okamoto; Xiaoping Yang; Greg Hinkle; Jesse S Boehm; Rameen Beroukhim; Barbara A Weir; Craig Mermel; David A Barbie; Tarif Awad; Xiaochuan Zhou; Tuyen Nguyen; Bruno Piqani; Cheng Li; Todd R Golub; Matthew Meyerson; Nir Hacohen; William C Hahn; Eric S Lander; David M Sabatini; David E Root
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-17       Impact factor: 11.205

8.  Meta-mining of neuroblastoma and neuroblast gene expression profiles reveals candidate therapeutic compounds.

Authors:  Katleen De Preter; Sara De Brouwer; Tom Van Maerken; Filip Pattyn; Alexander Schramm; Angelika Eggert; Jo Vandesompele; Frank Speleman
Journal:  Clin Cancer Res       Date:  2009-05-12       Impact factor: 12.531

9.  Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.

Authors:  David O Azorsa; Irma M Gonzales; Gargi D Basu; Ashish Choudhary; Shilpi Arora; Kristen M Bisanz; Jeffrey A Kiefer; Meredith C Henderson; Jeffrey M Trent; Daniel D Von Hoff; Spyro Mousses
Journal:  J Transl Med       Date:  2009-06-11       Impact factor: 5.531

10.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Authors:  Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono
Journal:  N Engl J Med       Date:  2009-06-24       Impact factor: 91.245

View more
  11 in total

Review 1.  How were new medicines discovered?

Authors:  David C Swinney; Jason Anthony
Journal:  Nat Rev Drug Discov       Date:  2011-06-24       Impact factor: 84.694

Review 2.  Treatment of traumatic brain injury with anti-inflammatory drugs.

Authors:  Peter J Bergold
Journal:  Exp Neurol       Date:  2015-06-23       Impact factor: 5.330

3.  Differential effects of procaspase-3 activating compounds in the induction of cancer cell death.

Authors:  Diana C West; Yan Qin; Quinn P Peterson; Diana L Thomas; Rahul Palchaudhuri; Karen C Morrison; Pamela W Lucas; Amy E Palmer; Timothy M Fan; Paul J Hergenrother
Journal:  Mol Pharm       Date:  2012-04-27       Impact factor: 4.939

Review 4.  CRISPR Approaches to Small Molecule Target Identification.

Authors:  Marco Jost; Jonathan S Weissman
Journal:  ACS Chem Biol       Date:  2018-01-25       Impact factor: 5.100

Review 5.  Discovery of small molecule cancer drugs: successes, challenges and opportunities.

Authors:  Swen Hoelder; Paul A Clarke; Paul Workman
Journal:  Mol Oncol       Date:  2012-03-03       Impact factor: 6.603

Review 6.  Genetic and proteomic approaches to identify cancer drug targets.

Authors:  G Roti; K Stegmaier
Journal:  Br J Cancer       Date:  2011-12-13       Impact factor: 7.640

7.  Chemical informatics and target identification in a zebrafish phenotypic screen.

Authors:  Christian Laggner; David Kokel; Vincent Setola; Alexandra Tolia; Henry Lin; John J Irwin; Michael J Keiser; Chung Yan J Cheung; Daniel L Minor; Bryan L Roth; Randall T Peterson; Brian K Shoichet
Journal:  Nat Chem Biol       Date:  2011-12-18       Impact factor: 15.040

Review 8.  The Power of Sophisticated Phenotypic Screening and Modern Mechanism-of-Action Methods.

Authors:  Bridget K Wagner; Stuart L Schreiber
Journal:  Cell Chem Biol       Date:  2016-01-21       Impact factor: 8.116

9.  Transfer and Expression of Small Interfering RNAs in Mammalian Cells Using Lentiviral Vectors.

Authors:  T D Lebedev; P V Spirin; V S Prassolov
Journal:  Acta Naturae       Date:  2013-04       Impact factor: 1.845

10.  Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitor.

Authors:  Gregory M Goldgof; Jacob D Durrant; Sabine Ottilie; Edgar Vigil; Kenneth E Allen; Felicia Gunawan; Maxim Kostylev; Kiersten A Henderson; Jennifer Yang; Jake Schenken; Gregory M LaMonte; Micah J Manary; Ayako Murao; Marie Nachon; Rebecca Stanhope; Maximo Prescott; Case W McNamara; Carolyn W Slayman; Rommie E Amaro; Yo Suzuki; Elizabeth A Winzeler
Journal:  Sci Rep       Date:  2016-06-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.